Belco Pharma Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Belco Pharma Pharmaceutical Export Portfolio Dataset — 2 Products, $417.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Belco Pharma — Pharmaceutical Exporter Profile (2026) | 2 Products, $417.9K Trade | TransData Nexus

Belco Pharma

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $417.9K Total Trade · DGFT Verified

Belco Pharma is an Indian pharmaceutical exporter with a total trade value of $417.9K across 2 products in 2 therapeutic categories. Based on 30 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Nifedipine ($366.1K), Vincristine ($51.8K), .

Belco Pharma — Export Portfolio & Destination Treemap

Belco Pharma pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Belco Pharma? — Company Overview & Market Position

Belco Pharma, established in 1975, is a WHO GMP-certified Indian pharmaceutical company specializing in the manufacturing and development of pharmaceutical formulations. The company offers a diverse portfolio of over 300 products across various dosage forms and therapeutic categories. Headquartered in Bahadurgarh, Haryana, India, Belco Pharma operates a state-of-the-art manufacturing facility equipped with advanced machinery, enabling it to cater to both domestic and international markets.

In January 2020, Belco Pharma Private Limited was incorporated with the Corporate Identification Number (CIN) U74999DL2020PTC360147. The company is privately held, with authorized capital of ₹1.00 million and paid-up capital of ₹0.10 million. As of the latest available data, Belco Pharma employs approximately 104 individuals, reflecting a 14% increase in workforce size over the past year.

What Does Belco Pharma Export? — Product Portfolio Analysis

Top Products by Export Value

1Nifedipine$366.1K 2Vincristine

Product Portfolio — Top 2 by Export Value

Belco Pharma exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nifedipine	Cardiovascular	$366.1K	27	1.2%	14
2	Vincristine	Oncology	$51.8K	3	2.6%	10

Belco Pharma exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $417.9K. The top category is Cardiovascular (87.6% of portfolio), followed by Oncology (12.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Belco Pharma — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Belco Pharma's manufacturing facility is strategically located in Bahadurgarh, Haryana, on the periphery of New Delhi, India's capital. This plant is equipped with modern machinery and adheres to stringent quality control measures, ensuring the production of high-quality pharmaceutical formulations. The facility's capabilities encompass the manufacturing of tablets, capsules, syrups, injections, and other dosage forms, catering to a wide range of therapeutic categories.

3Key Leadership

The leadership team at Belco Pharma includes:

Kapil Singla: Director since January 10, 2020.

Puneet Singla: Director since January 10, 2020.

The company's leadership is committed to maintaining high standards of quality and competitiveness in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Belco Pharma Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Belco Pharma has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Belco Pharma's adherence to international quality standards and regulatory requirements has enabled it to expand its footprint in these markets.

2Emerging Markets

Belco Pharma has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality and affordability has facilitated its entry into these regions. Additionally, Belco Pharma's products are registered in 25 countries worldwide, reflecting its global outreach and the trust placed in its offerings.

3Geographic Strategy

Belco Pharma's geographic strategy focuses on diversification and risk mitigation by expanding its presence across various international markets. The company's strategic tie-ups and joint ventures with multinational and national companies have bolstered its market position. By catering to both domestic and international markets, Belco Pharma aims to achieve sustainable growth and reduce dependence on any single market.

Belco Pharma — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Belco Pharma has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with FDA regulations. The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic products, facilitating market entry in the U.S. Belco Pharma's commitment to quality and regulatory compliance is evident in its FDA-approved Drug Master Files (DMFs), which detail the manufacturing processes and quality controls for its products. The company's facilities have undergone FDA inspections, reflecting its adherence to international standards.

2WHO & EU GMP

Belco Pharma's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO GMP), ensuring that its products meet international quality standards. The company has also obtained European Union Good Manufacturing Practice (EU GMP) certificates, facilitating access to the European market. These certifications underscore Belco Pharma's commitment to producing high-quality pharmaceutical formulations.

3CDSCO & Indian Regulatory

Belco Pharma — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Belco Pharma operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not publicly disclosed, the company's focus on quality, affordability, and regulatory compliance positions it favorably against competitors. Belco Pharma's strategic partnerships and diverse product portfolio further enhance its competitive edge.

2Key Differentiators

Belco Pharma's key differentiators include its extensive product portfolio of over 300 pharmaceutical formulations, adherence to international quality standards such as WHO GMP and EU GMP, and strategic collaborations with multinational and national companies. The company's commitment to providing quality medicines at reasonable prices underscores its dedication to patient well-being.

3Strategic Position

Belco Pharma's current strategic direction focuses on expanding its presence in both generics and branded generics segments. The company's emphasis on research and development enables it to introduce new products and delivery systems, enhancing patient compliance. Looking ahead, Belco Pharma aims to strengthen its position in existing markets and explore new business opportunities to achieve sustainable growth.

Buyer Due Diligence Brief — Evaluating Belco Pharma as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Belco Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with an estimated annual revenue of $20.9 million and a workforce of approximately 104 employees. The company's export volume and consistency are evident in its registration of over 200 products in 25 countries worldwide. Belco Pharma's commitment to quality and regulatory compliance enhances its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the facility's registration with the U.S. Food and Drug Administration.

WHO GMP Certification: Ensure the manufacturing facility holds a valid WHO GMP certificate.

EU GMP Certification: Verify the presence of an EU GMP certificate for the facility.

Frequently Asked Questions — Belco Pharma

How many pharmaceutical products does Belco Pharma export from India?

Belco Pharma exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Nifedipine ($366.1K), Vincristine ($51.8K). Total export value is $417.9K.

What is Belco Pharma's total pharmaceutical export value?

Belco Pharma's total pharmaceutical export value is $417.9K, based on 30 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Belco Pharma cover?

Belco Pharma exports across 2 therapeutic categories. The largest are Cardiovascular (87.6%, 1 products), Oncology (12.4%, 1 products).

Get Full Belco Pharma Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.